Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Markham, ON, CA. The stock last traded at $5.41, down 2.08% on the session, giving a market capitalisation of $52.1M. On trailing twelve-month figures it carries a trailing P/E of -4.03, a net margin of 0.0%. Its beta of 1.08 implies it has historically moved more than the broad market.
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Edesa Biotech, Inc. is most often compared with the following Healthcare names: